Single agent rituximab killing assays demonstrated that 4 of the 8 DLBCL cell lines were sensitive to rituximab treatment, corresponding to CD20 expression levels (S2A and S2B Fig). The gene discussed is MS4A1; the disease is diffuse large B-cell lymphoma.